Document is current
Any future updates will be listed below
-
Authors
Rau, Matthias
Thiele, Kirsten
Hartmann, Niels-Ulrik Korbinian
Schuh, Alexander
Altiok, Ertunc
Möllmann, Julia
Keszei, András P.
Böhm, Michael
Marx, Nikolaus
Lehrke, Michael
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
Projekt DEAL
- License Information
-
More Information
Article History
Received: 19 July 2020
Accepted: 15 November 2020
First Online: 7 January 2021
Ethics approval and consent to participate
: This study was approved by ethics committee of University Hospital Aachen (reference number: EK 250/16). All subjects gave written informed consent.
: Not applicable.
: MR, KT, NUKH, AS and JM report no potential conflict of interest, EA did receive personal fees from AstraZeneca und Novartis and receive research grants from Bayer und Novartis, MB served as a consultant and gave talks for Abbott, Amgen, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers-Sqibb, Cytokinetics, Medtronic, Novartis, Servier; NM has received support for clinical trial leadership from Boehringer Ingelheim, Novo Nordisk, served as a consultant to Boehringer Ingelheim, Merck, Novo Nordisk, AstraZeneca, BMS, received grant support from Boehringer Ingelheim, Merck, Novo Nordisk, and served as a speaker for Boehringer Ingelheim, Merck, Novo Nordisk, Lilly, BMS, and Astra Zeneca. NM declines all personal compensation from pharma or device companies. ML received grants and personal fees from Boehringer Ingelheim, MSD and Novo Nordisk, personal fees from Amgen, Sanofi, Astra Zeneca, Bayer and Lilly.
